Abstract

The present invention relates to methods of identifying cyclic peptide binders comprising D-amino acids to protein targets of interest. The invention further relates to cyclic peptide inhibitors of matrix metalloproteinase 7 (matrilysin), pharmaceutical formulations, and methods of use thereof.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The present invention relates to a process for dual-layer coating of a metal-containing material to thereby protect said material from corrosion; and to a metal-organic complex comprising a A-heterocyclic carbene (NHC) linked via the carbene to a metal atom, and via a nitrogen atom thereof, i.e., at least one of the nitrogen atoms of said A-heterocyclic carbene, to a crosslinked polymer network made of monomers polymerizable via thermal or radical polymerization.

IPC Classes  ?

• C09D 5/08 - Anti-corrosive paints
• C09D 7/65 - Additives macromolecular

Abstract

Methods of determining disease load or type in a subject suffering from a disease associated with cell death of a specific tissue or cell type are provided. Methods of determining a cell free DNA chromatin immunoprecipitation and sequencing (cfChIP-Seq) marker and methods of classifying a subject suffering from a disease are also provided.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/20 - Supervised data analysis

Abstract

Provided is a method of increasing lipid synthesis or accumulation in mammary epithelial cells (MECs) culture and optionally secretion therefrom. The method comprising contacting the MECs with an LXR agonist in the presence of a fatty acid to thereby increase lipid synthesis or accumulation and optionally secretion of lipids. Also provided is a method of producing synthetic fat globules, the method comprising: (a) isolating lipid droplets from cells in culture; (b) encapsulating the droplets with a lipid bilayer, thereby producing synthetic fat globules. Also provided are compositions produced thereby.

IPC Classes  ?

• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Methods of detecting cancer in a subject in need thereof, comprising ascertaining the methylation status of at least four methylation sites in the same double-stranded cell-free DNA (cfDNA) molecule and detecting the presence of at least two sites that are methylated and at least two sites that are unmethylated in the at least four methylation sites indicating that the subject suffers from cancer are provided. Methods of quantifying molecules of cfDNA and also provided, as are methods of detecting and quantifying plasma cell DNA. Methods of diagnosing multiple myeloma or predicting progression of smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma in a subject are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to isolated antibodies, fragments thereof and antibody-drug conjugates that bind to Lymphocyte antigen 6 family member K (LY6K) and their use for screening for LY6K-positive malignant cells or for therapeutic targeting of LY6K-positive malignant cells.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure relates to methods for the production of a cell-based product based on using synthetic promoters or a cellular input-output unit thereof, configured for controlling the expression of at least one nucleic acid sequence of interest, upon sensing dynamic cellular- and/or environmental- state and/or condition, that leads to a desired phenotype of the cells. The present disclosure further provides cell-based products, in particular, animal cell-based meat products (ACBM).

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The invention generally concerns a bioactive composition of a nanocellulose and a microorganism and uses thereof in soil rehabilitation.

IPC Classes  ?

• C08L 1/02 - CelluloseModified cellulose
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
• B09C 1/10 - Reclamation of contaminated soil microbiologically or by using enzymes
• B09C 1/08 - Reclamation of contaminated soil chemically
• C08L 1/04 - OxycelluloseHydrocellulose

Abstract

The technology generally concerns perovskite-based devices having improved transparency and uses thereof.

IPC Classes  ?

• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Abstract

The technology concerns a construct comprising at least one tissular region and at least one polymeric region for use as an implant.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/14 - Macromolecular materials
• B32B 3/26 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids
• B32B 9/02 - Layered products essentially comprising a particular substance not covered by groups comprising animal or vegetable substances
• B32B 9/04 - Layered products essentially comprising a particular substance not covered by groups comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance
• B32B 15/02 - Layered products essentially comprising metal in a form other than a sheet, e.g. wire, particles
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method

Abstract

Method and compositions that comprise an agent that reduces nNOS activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.

IPC Classes  ?

• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to combination the combination, pharmaceutical compositions and kits comprising at least two small molecule inhibitors (SMIs) of respectively at least two proteins of different signaling pathways of retinal disease and methods for treating a retinal disease.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/42 - Oxazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 27/02 - Ophthalmic agents

Abstract

The technology disclosed herein generally concerns detection of enzymes and other biological materials by use of sialylated glycan-based detection units.

IPC Classes  ?

• C12Q 1/40 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving amylase
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• G01N 27/327 - Biochemical electrodes

Abstract

The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and/or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular/hepatic function and/or improving cardiovascular/hepatic disease or disorders.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/107 - Emulsions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A23L 33/12 - Fatty acids or derivatives thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A23L 33/15 - Vitamins
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C09K 23/00 - Use of substances as emulsifying, wetting, dispersing, or foam-producing agents

Abstract

The invention relates to peptidomimetic inhibitors of calreticulin, to their prodrugs and to pharmaceutical compositions comprising them. Specifically provided are cyclic peptidomimetic s and their prodrugs having a lipophilic charge mask, thus metabolically stable and highly bioavailable. Methods for treatment of autoimmune diseases and other conditions associated with calreticulin are also provided.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 27/02 - Ophthalmic agents

Abstract

The detection of enzymes and other biological materials is accomplished by use of sialylated glycan-based detection units.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance

Abstract

Haploid human embryonic stem cells and cell lines, haploid multipotent human cells, and haploid differentiated human cells are provided. In addition, methods of making and using the haploid human cells are provided.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/075 - OocytesOogonia

Abstract

The invention provides a process for treating sludge, comprising steps of digesting the sludge and/or dewatering the sludge, wherein either sludge digestion, sludge dewatering or both is (are) preceded by the addition of hydroxide compound and hydrogen peroxide to the sludge. Sludge treatment installation is also described.

IPC Classes  ?

• C02F 11/143 - Treatment of sludgeDevices therefor by de-watering, drying or thickening with addition of chemical agents using inorganic substances
• C02F 3/28 - Anaerobic digestion processes
• C02F 11/04 - Anaerobic treatmentProduction of methane by such processes
• C02F 11/06 - Treatment of sludgeDevices therefor by oxidation
• C02F 101/30 - Organic compounds

Abstract

Some embodiments relate to a method and system for quantum error mitigation (QEM) of noise in a quantum system configured to execute a quantum circuit, wherein the noise induces an error on a noise-free evolution U of the quantum circuit. The method comprises: defining a noisy evolution operator, , associated with a noisy evolution of the quantum circuit, operator, , configured to execute a Hamiltonian drive H(t) which generates the noise-free evolution U in the absence of noise; defining a corresponding inverse noisy evolution operator, , being a pulse inverse operator configured to execute a corresponding inverse Hamiltonian drive HI(t); and creating an operator , which is an approximate square of a noise channel associated with the operator , said operator representing execution of the Hamiltonian drive H(t) followed by execution of the corresponding inverse Hamiltonian drive HI(t) thereby enabling error mitigation of noise in the quantum system.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation

Abstract

The present disclosure is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The disclosure discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The disclosure also discloses methods and compositions for targeted genome editing in the pest in order to achieve a reduction in pest infestation through disruption of protein activity. The disclosure is also directed to methods for making transgenic plants that express the double stranded RNA molecules and targeted genome editing constructs for use in protecting plants from pest infestation.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• A01H 5/10 - Seeds
• A01N 63/60 - Isolated nucleic acids

Abstract

The present disclosure is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The disclosure discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The disclosure also discloses methods and compositions for targeted genome editing in the pest in order to achieve a reduction in pest infestation through disruption of protein activity. The disclosure is also directed to methods for making transgenic plants that express the double stranded RNA molecules and targeted genome editing constructs for use in protecting plants from pest infestation.

IPC Classes  ?

• A01N 57/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
• A01P 7/04 - Insecticides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

The present invention is directed to methods for diagnosing Parkinson's disease (PD) with or without dementia in a subject. The present invention is further directed to methods for determining the severity of PD in a subject afflicted therewith, for determining responsiveness to anti PD therapy of a subject administered therewith, and for treating a subject afflicted with PD.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The technology generally concerns antimicrobial materials and uses thereof.

IPC Classes  ?

• A01N 37/40 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system having at least one carboxylic group or a thio-analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

The present invention is directed to cathepsin inhibitor conjugates, precursors and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with abnormal cathepsin activity in a subject in need thereof are also provided.

IPC Classes  ?

• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 207/448 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The invention provides compositions comprising ladostigil, being a colonic delivery composition, including methods and uses thereof.

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure relates to a method and composition for improving at least one plant-related parameter in cucurbitaceous the method comprising: contacting a plant or plant part with an amount of at least one bacterium, the at least one bacterium, the amount of said at least one bacterium being effective to provide an improvement in said at least one plant-related parameter. Also disclosed is a kit comprising the at least one bacterium and instructions for use of the at least one bacterium for improving at least one plant-related parameter in cucurbitaceous.

IPC Classes  ?

• A01N 63/25 - Paenibacillus
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 21/00 - Plant growth regulators

Abstract

The technology subject of the application concerns to fluorine-free superhydrophobic coatings of amino acid-bound nanoparticles.

IPC Classes  ?

• C09D 5/16 - Anti-fouling paintsUnderwater paints
• C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
• C09D 7/40 - Additives

Abstract

The invention generally concerns photoexcitable films and devices implementing same, which comprise chirally ordered cellulose nanocrystals (CNC) arrangements and QDs.

IPC Classes  ?

• H10K 30/35 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains comprising inorganic nanostructures, e.g. CdSe nanoparticles
• H10K 50/115 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising active inorganic nanostructures, e.g. luminescent quantum dots
• C09K 11/00 - Luminescent, e.g. electroluminescent, chemiluminescent, materials
• H10H 20/851 - Wavelength conversion means

Abstract

A computer-implemented method comprising: receiving, as input, matrices A, B and a linear combination of blocks for a main multiplications operation with respect to the input matrices A, B; applying an inner matrix multiplication algorithm to calculate separately: (i) the main multiplications of input matrices A, B, using the linear combination of blocks, (ii) correction terms for the input matrix A, and (iii) correction terms for the input matrix B; and combining the results of the calculating, to obtain a matrix multiplication operation result C of the input matrices A, B.

IPC Classes  ?

• G06F 17/16 - Matrix or vector computation

Abstract

The present invention, is directed to a method for selecting an improved genetically modified Solanum plant, the method including: determining the presence of at least one inactive allele of auxin responsive factor (ARF) 8 gene in the genome of the genetically modified Solanum plant or a part derived therefrom; and (b) selecting a genetically modified Solanum plant determined as having a genome including the at least one inactive allele of ARF8 gene, wherein the improvement is at least any one of: (i) increased yield; (ii) increased resistance to a pathogen; (iii) earlier fruit setting; and (iv) any combination of (i) to (iii), compared to a wild-type variant of said Solanum plant, thereby, selecting an improved genetically modified Solanum plant.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

Novel inhibitors of MetAp2 enzymatic activity and uses thereof are provided.

IPC Classes  ?

• C07D 303/40 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61P 35/00 - Antineoplastic agents
• C07D 303/46 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals

Abstract

The invention generally discloses short and ultrashort peptides with improved antimicrobial properties.

IPC Classes  ?

• A01N 37/46 - N-acyl derivatives
• A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• C07K 5/06 - Dipeptides
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr

Abstract

The present invention relates to a method of determining the trapped volume and the trapped aqueous volume of a plurality of liposomes in a liposomal composition. The method can be used for calculating the concentration of an active pharmaceutical ingredient entrapped within the liposomes and for quality assurance of a pre-formed liposomal composition.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• G01N 33/15 - Medicinal preparations

Abstract

The present invention relates to novel peptides having immunomodulatory activity, compositions comprising same and use thereof. More specifically, disclosed herein are synthetic peptides capable of inhibiting or controlling immune activation, and methods of using same in the treatment of autoimmunity, immune-related adverse events and other conditions associated with the inappropriate or excessive immune responses.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• A61P 37/02 - Immunomodulators
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are peptide sequences derived from human NAF-1 protein wherein it is demonstrated that addition of positively charged moieties, including positively charged amino acids, to the C-terminus improves cancer cell killing without increasing toxicity. Also disclosed are pharmaceutical compositions and methods of use of the peptides.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 35/00 - Antineoplastic agents
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention, provides, inter alia, a fresh produce including a spore-forming probiotic bacterial strain colonizing a tissue of the fresh produce, wherein at least 20% of CPU of the spore-forming bacterial strain colonizing the tissue of the fresh produce are in a spore form. Further provided are a kit including the fresh produce and a suitable container, as well as a method for preparing same.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 35/66 - Microorganisms or materials therefrom
• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes

Abstract

Disclosed herein are genetically modified plants having altered biological activity of 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Methods of producing these genetically modified plants are also disclosed.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

Abstract

A system for growing cells comprising a bioreactor chamber for growing the cells, a delivery system delivering a perfusion solution to the bioreactor chamber for perfusion of the perfusion solution through the cells, a dialysis system having a dialyzer, a dialysate for performing a dialysis and a filter for reducing ammonia content in said dialysate, and a controller that circulates the perfusion solution through the dialyzer and the dialysate through the filter.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The invention provides synthetic compounds having psychedelic bioactivity, compositions comprising them, methods of their preparation and uses thereof in the treatment of diseases, symptoms and disorders.

IPC Classes  ?

• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin

Abstract

Methods of treating fragile X syndrome by administering agents that reduce expression or function of various proteins are provided. Methods of determining suitability to be treated by the methods of the invention are also provided.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present invention is directed to a multi scaffold-cell construct including: (a) a first scaffold including photosynthetic cells embedded therein, thereon, or both; and (b) a second scaffold comprising non-photosynthetic cells embedded therein, thereon, or both, wherein the first scaffold and the second scaffold are positioned at a distance from one another allowing oxygen flow from the first scaffold to second scaffold.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• A61L 27/00 - Materials for prostheses or for coating prostheses
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

An electronic device is presented comprising: at least one basic block, and a control circuit. Each basic block comprises an active unit configured and operable to be responsive to one of circularly polarized electromagnetic field or circularly polarized spin current by a change in magnetization orientation in the active unit. The control circuit is configured and operable to carry out one of the following: (i) monitoring changes in at least one electrical property of the active unit to thereby monitor the change in magnetization orientation in the active unit in response to the circularly polarized electromagnetic field being applied to the active unit, or (ii) managing generation of the circularly polarized spin current in the active unit to thereby induce said change in the magnetization orientation in the active unit.

IPC Classes  ?

• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect

Abstract

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAK1) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

A computer-implemented method, comprising: receiving input data associated with a target case; applying a trained neural embedding module to learn embeddings representing the input data; constructing, based on the learned embeddings, at least one retrieval query vector configured to identify one or more relevant external knowledge items, based on a similarity between the learned embeddings and embeddings of the external knowledge items; executing the at least one retrieval query on at least one external data source, to retrieve the one or more relevant external knowledge items; generating an aggregated embeddings representation of the input data, and an aggregated embeddings representation of the one or more relevant external knowledge items; and inferencing a prediction module on the generated aggregated embeddings of the input data and the one or more relevant external knowledge items, to output a target prediction associated with the target case.

IPC Classes  ?

• G06F 16/903 - Querying
• G06F 16/906 - ClusteringClassification
• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention provides psychoactive compounds. Compositions comprising them and methods of their preparation and use in the treatment of metal diseases or disorders.

IPC Classes  ?

• C07C 49/403 - Saturated compounds containing a keto group being part of a ring of a six-membered ring
• C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 25/20 - HypnoticsSedatives
• A61P 25/24 - Antidepressants
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/22 - Anxiolytics
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Provided are systems, compositions, methods and devices for manufacturing artificial skin substitutes and related products mimicking the morphology and appearance of human skin. Applications of the invention pertain to the fields of regenerative medicine and pharma with products that can support tissue replacement and tissue engineering. The most immediate applications pertain to the field of cosmetics with the development of pigmented compositions that can be incorporated in various skin care and cosmetic foundation products.

IPC Classes  ?

• A61K 8/65 - CollagenGelatinKeratinDerivatives or degradation products thereof
• A61Q 1/02 - Preparations containing skin colorants, e.g. pigments
• A61Q 19/00 - Preparations for care of the skin
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present disclosure is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The disclosure discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The disclosure also discloses methods and compositions for targeted genome editing in the pest in order to achieve a reduction in pest infestation through disruption of protein activity. The disclosure is also directed to methods for making transgenic plants that express the double stranded RNA molecules and targeted genome editing constructs for use in protecting plants from pest infestation.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The disclosure discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The disclosure also discloses methods and compositions for targeted genome editing in the pest in order to achieve a reduction in pest infestation through disruption of protein activity. The disclosure is also directed to methods for making transgenic plants that express the double stranded RNA molecules and targeted genome editing constructs for use in protecting plants from pest infestation.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• C12N 9/22 - Ribonucleases

Abstract

Methods of treating lipotoxicity in the lungs by administering a metabolic regulator are provided.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A computer-implemented method comprising: receiving two or more input matrices for a multiplication operation; determining, for each of the input matrices, a series of transformations, and applying the series of transformations respectively to the input matrices to obtain transformed the input matrices, wherein each of the series of transformations reduces a number of arithmetic operations required to perform the multiplication operation, given a desired value of communication costs required to perform the multiplication operation using the computer system, and wherein each of the series of transformations is performed over two or more recursions, wherein at least one of the recursions comprises at least two the transformations; applying a recursive bilinear computation to the transformed two or more input matrices, thereby producing a transformed multiplied matrix; and determining an output series of transformations which are applied to the transformed multiplied matrix, to obtain a product of the input matrices.

IPC Classes  ?

• G06F 17/16 - Matrix or vector computation

Abstract

The application discloses a stereocomplex of a hydrophilic stereoregular biodegradable polyester and a peptide active agent or a protein for delivery of peptides or proteins in vivo.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A61K 38/28 - Insulins
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

The invention contemplates metal-peptide assemblies with superior antimicrobial activity, especially copper-peptide complexes wherein the peptide comprises DOPA and Phe moieties.

IPC Classes  ?

• A01N 59/20 - Copper
• A01N 37/46 - N-acyl derivatives
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides

Abstract

The technology disclosed herein concerns de-hydroxylated cardiac steroid of formula (I) and uses thereof in medicine. The technology disclosed herein concerns de-hydroxylated cardiac steroid of formula (I) and uses thereof in medicine.

IPC Classes  ?

• C07J 19/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 by a lactone ring
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein is a pharmaceutical composition comprising a therapeutically effective amount of an antioxidant for use in a method for treating or preventing a fibrotic-related condition in a subject in need thereof.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 17/18 - Antioxidants, e.g. antiradicals

Abstract

The present invention provides cannabinoid derivatives, compositions comprising them and uses thereof in a method of treating fungal infections.

IPC Classes  ?

• C07C 39/08 - Dihydroxy benzenesAlkylated derivatives thereof
• C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
• C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07C 69/18 - Acetic acid esters of trihydroxylic compounds

Abstract

The invention generally concerns reversible surfactant and emulsions containing same.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 8/06 - Emulsions
• A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61Q 5/00 - Preparations for care of the hair
• A61Q 19/00 - Preparations for care of the skin
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

A system and method of determining white matter packing in a brain of a subject by at least one processor may include utilizing a Magnetic Resonance Imaging (MRI) device to perform a multiple-echo sequence scan of a region of interest (ROI) of the subject's white matter. Based on the multiple-echo sequence scan, the at least one processor may obtain a Magnetic Resonance (MR) data element representing exponential decay of MR signal in a plurality of voxels within the ROI. The at least one processor may analyze the MR data element to extract, for at least one voxel of the ROI, a white matter (WM) packing parameter value corresponding to that at least one voxel. The WM packing parameter may be indicative of structural packing of non-water material, on a sub-voxel scale.

IPC Classes  ?

• G01R 33/50 - NMR imaging systems based on the determination of relaxation times
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are novel NOS inhibitor compounds. Also disclosed herein, are methods for treating, ameliorating, and/or reducing the severity of NOS-related cancer, or a symptom associated therewith in a subject. The compounds described herein may be administered with a particular route of delivery, dosing regimen, and dosing schedule.

IPC Classes  ?

• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/04 - Nitro compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A process for preparing a meat-derived antioxidant, comprising cooking or heat drying meat by direct contact with a hot surface to form a crust and comminuting an isolated form of the crust to obtain crust particles suitable for use as a food additive. The meat crust, and its use as a food additive antioxidant, are also provided by the invention.

IPC Classes  ?

• A23L 13/10 - Meat meal or powderGranules, agglomerates or flakes

Abstract

The invention generally concerns etched metallic surface containing nanoparticle-loaded nanopores.

IPC Classes  ?

• C22C 1/08 - Alloys with open or closed pores
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C22C 3/00 - Removing material from non-ferrous alloys to produce alloys of different constitution
• C23G 1/02 - Cleaning or pickling metallic material with solutions or molten salts with acid solutions
• C23G 1/10 - Other heavy metals
• C23G 1/12 - Light metals
• C25F 3/02 - Etching
• A61L 27/04 - Metals or alloys
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Abstract

Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed herein are compositions comprising novel nNOS inhibitors. Also disclosed herein, are methods for treating, ameliorating, and/or reducing the severity of neurological conditions, including neurodevelopmental conditions and/or neurodegenerative disorders, or a symptom associated therewith in a subject. The compositions described herein may be administered with a particular route of delivery, dosing regimen, and dosing schedule.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein is a system for magnetic testing of samples. The system includes: (i) a magnetic field generator configured to, by rotating a magnet(s), which is permanent, produce a temporally modulated magnetic field over a region whereat a sample is positioned; (ii) a waveguide positioned adjacently to the sample; (iii) a first sensor configured to obtain a first signal by directly and/or indirectly measuring a modulation rate of the produced magnetic field; (iv) an electromagnetic signal generator coupled to a first end of the waveguide; (v) a second sensor coupled to a second end of the waveguide and configured to obtain a measured signal by measuring a power of an electromagnetic signal transmitted through the waveguide; and (vi) a heterodyne-based demodulator communicatively associated with the first and second sensors and configured to use a reference signal, constituted by or obtained from the first signal, to demodulate the measured signal.

IPC Classes  ?

• G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance

Abstract

The disclosure concerns viscous or gelled delivery systems based on oily nano-domains dispersed in a viscosified/gelled continuous aqueous phase, and suitable for prolonged and/or sustained topical delivery of various active compounds.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/723 - Xanthans
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10Kb C-to-T, optionally in combination with additional CF therapeutics.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The invention provides compounds and uses thereof in the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy or oxidative stress, and methods of their preparation.

IPC Classes  ?

• C07D 249/12 - Oxygen or sulfur atoms
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61P 35/00 - Antineoplastic agents
• A61P 39/00 - General protective or antinoxious agents
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/18 - One oxygen or sulfur atom
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 233/84 - Sulfur atoms
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles

Abstract

A method of generating a biofilm of nomadic bacteria. The method comprises: (a) culturing the nomadic bacteria in an acidic environment under conditions that promote generation of a V-type structure of the nomadic bacteria; and subsequently (b) culturing said nomadic bacteria having a V-type structure on an adherent surface, thereby generating the biofilm comprising the nomadic bacteria. Conditioned media of nomadic bacteria are also disclosed and uses thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/22 - Bacillus
• C12R 1/125 - Bacillus subtilis
• C12R 1/245 - Lactobacillus casei
• C12R 1/25 - Lactobacillus plantarum

Abstract

The application discloses a formulation and method for increasing bioavailability of an orally administered drug.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/05 - Phenols
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 36/67 - Piperaceae (Pepper family), e.g. Jamaican pepper or kava
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

The invention provides polymer compositions comprising antimicrobial components capable of reducing or delaying the formation of biofilms on the surface of polymer materials and articles made therefrom. The invention further provides processes of manufacturing such compositions and various applications thereof.

IPC Classes  ?

• A01N 31/08 - Oxygen or sulfur directly attached to an aromatic ring system
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 59/16 - Heavy metalsCompounds thereof
• A01N 59/20 - Copper
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides
• A01N 25/10 - Macromolecular compounds
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group

Abstract

The invention generally concerns formulations of cannabinoids for cosmetic purposes. To that end, the invention provides formulations with improved stability and topical delivery, as well as improved efficacy in terms of anti-inflammatory, anti-aging effects, and skin protective effects overall.

IPC Classes  ?

• A61K 8/34 - Alcohols
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
• A61Q 19/08 - Anti-ageing preparations

Abstract

The invention generally relates to a digital manufacturing system unit for manufacturing a food product, the system unit being a non-partitioned system unit comprising a raw material metering and mixing unit, a food product assembly unit and a food product cooking unit, the system unit being configured and operable to receive one or more customer-specified requirement relating to a food product profile and execute a set of machine instructions specifying a manufacturing process suitable for manufacturing the food product based on the food product profile, thereby manufacturing the food product. The invention also relates to a method for digital manufacturing a food product using such a system.

IPC Classes  ?

• A23P 20/20 - Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
• A23P 20/25 - Filling or stuffing cored food pieces, e.g. combined with coring or making cavities
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 40/10 - Pre-treatment

Abstract

Method and compositions that comprise an agent that reduces nNOS Open arm activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.

IPC Classes  ?

• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides stabilized calcitonin analogues that demonstrate improved stability and bioavailability. The present invention also provides pharmaceutical compositions of the stabilized calcitonin analogues as well as their use in methods of treating and preventing calcium-related and bone-related disorders and diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/23 - Calcitonins
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C07K 14/585 - Calcitonins

Abstract

RRR.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

Nucleic acid molecules configured to specifically express a sequence of interest in a cancer cell, comprising: a transcription factor binding region comprising 3-10 repeats of a transcription factor binding site, a minimal promoter and the sequence of interest operatively linked to the transcription factor binding region and minimal promoter, wherein the transcription factor is selected from SOX9, GATA10, TCF7L1, LEF1, MYBL2 and MYB are provided. Nucleic acid molecule systems and compositions comprising the nucleic acid molecules are also provided as are methods of treating cancer.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• A61P 35/00 - Antineoplastic agents

Abstract

A traveling wave kinetic inductance parametric amplifier is presented. The amplifier includes a microstrip structure defining a parallel plate capacitor element formed by first and second electrically conductive layers spaced by a dielectric spacer layer. The first electrically conductive layer is made of superconducting material composition having desirably high kinetic inductance and being configured as a nanoscale thickness strip.

IPC Classes  ?

• H03F 7/00 - Parametric amplifiers
• H01P 3/08 - MicrostripsStrip lines

Abstract

The present invention relates to sesame plants resistant to herbicides that inhibit the plant enzyme acetolactate synthase (ALS), and further to compositions and methods for producing the same.

IPC Classes  ?

• A01H 6/66 - Pedaliaceae, e.g. sesame
• C12N 9/10 - Transferases (2.)
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

The present technology generally provides printed 3D alumina structures and uses thereof.

IPC Classes  ?

• C04B 35/115 - Translucent or transparent products
• C04B 35/624 - Sol-gel processing
• C04B 35/632 - Organic additives
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof
• C04B 35/634 - Polymers

Abstract

The technology subject of the present application concerns antimicrobial and/or antifouling materials and films made therefrom.

IPC Classes  ?

• A01N 25/24 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
• A01N 25/10 - Macromolecular compounds
• A01N 59/20 - Copper
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

A method comprising: receiving (i) a first OCT scan, and (ii) a second, subsequent, OCT scan, each comprising one or more two-dimensional (2D) scan images of an eye of a subject; receiving a first and second retinal images of the eye of the subject, associated with the first and second OCT scans; matching corresponding first and second pixel column patches, each comprising one or more pixel columns, associated respectively with the scan images of the first and second OCT scans, based, at least in part, on performing image registration between the scan images of the first and second OCT scans; and using the matched corresponding first and second pixel column patches as input for a trained machine learning model, wherein an output of the trained machine learning model classifies the second pixel column patches as representing retinal atrophy or not representing retinal atrophy.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

The invention generally concerns a method for forming fully recyclable thermoset polymers, and products obtained by the method.

IPC Classes  ?

• C08G 12/06 - Amines
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• C08G 69/40 - Polyamides containing oxygen in the form of ether groups
• C08G 73/06 - Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromoleculePolyhydrazidesPolyamide acids or similar polyimide precursors
• C08G 75/26 - Polythioesters
• C09D 11/30 - Inkjet printing inks
• C09D 177/06 - Polyamides derived from polyamines and polycarboxylic acids
• C09D 179/04 - Polycondensates having nitrogen-containing heterocyclic rings in the main chainPolyhydrazidesPolyamide acids or similar polyimide precursors

Abstract

The disclosure relates to the technique, including systems and methods, for use in optical topographical and/or tomographic 3D imaging of a sample. The system may include (a) a lens unit, chromatically dispersive so that its focal length varies depending on a light wavelength, the lens unit being configured to pass therethrough polychromatic light arriving from and originated at a sample, while selectively collimating those spectral components of the polychromatic light which are in focus based on their wavelengths and origins; and (b) an etalon structure accommodated in an optical path of light being output from the lens unit to receive the collimated light, said etalon structure being configured to operate with multiple resonant wavelengths and to provide respective spectral transmittance peaks at said resonant wavelengths.

IPC Classes  ?

• G01J 3/26 - Generating the spectrumMonochromators using multiple reflection, e.g. Fabry-Perot interferometer, variable interference filter
• G01J 3/18 - Generating the spectrumMonochromators using diffraction elements, e.g. grating
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present disclosure generally relates to the field of solid phase synthesis and methods for synthesizing peptides and employing solid phase synthesis.

IPC Classes  ?

• C07K 1/04 - General processes for the preparation of peptides on carriers

Abstract

A support device for a pulsating organ is comprised of a structure formed at least partially of one or more polymers. The structure is configured to transition, in response to a stimulus, between a placement shape, in which the support device is dimensioned larger than the dimensions of the organ, and a treatment shape, in which the support device provides therapeutic support to the organ; wherein the treatment shape is smaller than the placement shape. Preferably, the polymers are shape memory polymers. The support device may be manufactured in an initial shape in which the one or more shape memory polymers are in their permanent shapes, and the placement shape is larger than or equivalent to the initial shape. Optionally, the stimulus is application of an aqueous medium. Embodiments of support devices may be used for treatment of heart failure with reduced ejection fraction and with preserved ejection fraction.

IPC Classes  ?

• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The invention provides a novel class of microparticles suitable for inducing or causing embolism to blood microvessels.

IPC Classes  ?

• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials
• A61K 9/50 - Microcapsules
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

The present invention provides monoclonal antibodies that recognize human CD 112R with high affinity and specificity and inhibit its binding to Nectin-2. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Nanoparticles comprising a nucleic acid molecule encoding human ubiquitin-like protein 5 (UBL5) or human UBL5 protein are provided. Methods of treating a disease, disorder or condition characterized by mitochondrial stress are provided. Expression vectors, nucleic acid molecules, peptides, pharmaceutical compositions and methods of identifying a gene for use in gene therapy, targeting an agent to a CD44 expressing cell and producing a therapeutic nanoparticle are also provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/86 - Viral vectors
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention provides compositions and methods for preserving pancreatic β-cell populations and for the treatment of diabetes. In particular, embodiments of the invention relate to the use of newly identified prostaglandin receptor 3 (EP3) antagonists that are exceptionally effective in enhancing the viability and/or activity of pancreatic P cells.

IPC Classes  ?

• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention provides a method of treating a disease or disorder characterized by electro-mitochondrial desynchronization in a subject in need thereof, comprising confirming the disease or disorder is characterized by electro-mitochondrial desynchronization in the subject and administering an agent that modulates mitochondrial calcium concentration and/or increases mitochondrial calcium channel activity in a tissue of the disease or disorder in the subject. Multichambered cardiac organoids comprising cardiomyocytes and endothelial cells and at least two chambers beating in synchrony are provided. Further provided are methods of using the multichambered cardiac organoid, methods of producing a cardiac organoid. Systems for making measurements within cellular aggregates or tissues and the use of same for testing therapeutic agents is also provided.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Pharmaceutical compositions comprising a non-proliferating cell of an immortalized natural killer (NK) cell line exogenously expressing the IncRNA NeST, CD 16 or a functional fragment thereof or an anti-CD19 CAR are provided. The use of the compositions in treating a CD48 expressing cancer in a subject in need thereof, are also provided. Methods for producing a non-proliferating NK cell and pharmaceutical compositions comprising the non- proliferating NK cell obtainable by the methods disclosed herein are also provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07K 14/735 - Fc receptors

Abstract

The present invention relates to a method for forming a protective coating on a plant tissue by applying a first aqueous solution containing a crosslinking agent to a postharvest plant matter having an external surface that includes a first segment which is covered by natural skin and a second segment which has an exposed surface, wherein the first aqueous solution is applied at least upon the exposed surface of the second segment of the postharvest plant matter; and subsequently applying a second aqueous solution comprising a polysaccharide which is susceptible to crosslinking by the crosslinking agent at least upon the exposed surface of the second segment of the postharvest plant matter, thereby forming a protective coating on the exposed surface of the second segment of the postharvest plant matter due to crosslinking of the polysaccharide by the crosslinking agent.

IPC Classes  ?

• A23B 7/16 - Coating with a protective layerCompositions or apparatus therefor
• A23B 7/154 - Organic compoundsMicroorganismsEnzymes
• A23B 7/157 - Inorganic compounds

Abstract

The technology disclosed herein concerns 3D printed foams and porous objects having a multiscale porosity.

IPC Classes  ?

• B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Abstract

A robotic chef includes a feeder station, each feeder comprising a dispensing outlet and configured to dispense a raw food material; one or more cookers adapted for shaping and cooking the raw food material, wherein the cooking station is axially above or below the feeder station; a lift with a platform; and a controller. The controller controls movement of the platform between a loading position, in which the platform is below a dispensing outlet of a feeder, to thereby receive the raw food material, and a discharge position in which the platform is adjacent to a cooking surface of a cooker. Each feeder includes a knife having an outlet cover that is moveable between a closed state, in which the outlet cover covers the dispensing outlet, and an open state. The lift includes an actuator for displacing the outlet cover from the closed state to the open state.

IPC Classes  ?

• G07F 17/00 - Coin-freed apparatus for hiring articlesCoin-freed facilities or services
• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• A47J 37/04 - Roasting apparatus with movably-mounted food supports or with movable heating implementsSpits
• A47J 37/06 - RoastersGrills Sandwich grills
• H05B 6/12 - Cooking devices

Abstract

The invention generally discloses a hydrogel material formed of nanocelluloses acrylamide.

IPC Classes  ?

• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/38 - Animal cells
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention relates to a chimeric polypeptide for use in in-vitro tissue engineering, the chimeric polypeptide comprising a cellulose binding domain (CBD); at least one extracellular matrix (ECM) module; and optionally at least one linker, wherein the at least one ECM module comprises an ECM protein selected from vitronectin, fibronectin, laminin, collagen, elastin, E-cadherin, tenascin-C, perlecan, small integrin-binding ligand N-linked glycoproteins (SIBLING), and a functional portion thereof; and/or an ECM motif selected from RGD, GRGDSP, PHSRN, GFOGER, IKVAV, and YIGSR.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• A23L 13/00 - Meat productsMeat mealPreparation or treatment thereof
• C07K 14/475 - Growth factorsGrowth regulators
• C07K 17/12 - Cellulose or derivatives thereof
• C12N 5/07 - Animal cells or tissues
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A cooker includes a bottom heater and a top heater defining therebetween an axially controllable cooking space for receiving therein an uncooked food product and for cooking the food product. A prepared food tray is adjacent to the cooking space. A dragger with a dragging surface is configured to displace the cooked food product from the cooking space to the prepared food tray. An integrated drive system is configured for controlling an axial dimension of the cooking space and a horizontal displacement of the dragger. The drive system may include: a belt drive; a cooking space shaft, and a cooking space clutch for selectively connecting and disconnecting the cooking space shaft from the belt drive; a dragger shaft, and a dragger clutch for selectively connecting and disconnecting the dragger shaft from the belt drive; and a controller for controlling operation of the belt drive and the clutches.

IPC Classes  ?

• G07F 17/00 - Coin-freed apparatus for hiring articlesCoin-freed facilities or services
• A47J 37/04 - Roasting apparatus with movably-mounted food supports or with movable heating implementsSpits
• A23L 5/10 - General methods of cooking foods, e.g. by roasting or frying
• A47J 37/06 - RoastersGrills Sandwich grills
• H05B 6/12 - Cooking devices

Abstract

The present invention is directed to methods for determining an autism spectrum condition in a subject. Further provided is a kit suitable for determining an autism spectrum condition.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems